{
  "metadata": {
    "timestamp": "2025-12-16T23:25:01.429832",
    "genes": [
      "AC103770.1",
      "AC008467.1",
      "LINC00326",
      "AC024901.1",
      "IL12RB2",
      "LINC01208",
      "AC068633.1",
      "LINC01482",
      "DNAH12",
      "AC009264.1",
      "CORIN",
      "AC019117.1",
      "LINC01933",
      "LINC01934",
      "AC078923.1",
      "MSH4",
      "SGO1-AS1",
      "AC105290.1",
      "AC092813.1",
      "SPDYA",
      "AC005487.1",
      "AC097522.2",
      "AC005355.1",
      "AL078604.4",
      "NUP210L",
      "LEKR1",
      "KLRD1",
      "IL34",
      "IGF2BP2",
      "TPH2",
      "NFE2L3",
      "ASB15",
      "GRK7",
      "C5ORF66",
      "FER1L6",
      "PKD1L1",
      "AL390957.1",
      "SLC10A1",
      "COL21A1",
      "AL590434.1",
      "AC092353.1",
      "AL136456.1",
      "LINC02763",
      "IL12A-AS1",
      "LINC00880",
      "LINC00589",
      "LINC01504",
      "MGAM",
      "LINC01214",
      "AC010343.3",
      "LINC02073",
      "LINC01823",
      "LINC02196",
      "LINC01588",
      "LINC02408",
      "LINC02341",
      "LINC02398",
      "AL512328.1",
      "ARHGEF28",
      "TG",
      "LINC02613",
      "MANBA",
      "AC084816.1",
      "AC004949.1",
      "AL008633.1",
      "PXDNL",
      "LINC02680",
      "CLVS1",
      "PPP1R1C",
      "LINC02150",
      "PTGER3",
      "DCDC2C",
      "LINC00616",
      "TSPAN8",
      "LINC00881",
      "GABRR2",
      "AC015845.2",
      "LINC00636",
      "TRIM59",
      "LINC01182",
      "NPR3",
      "LINC01811",
      "AL136441.1",
      "AL162414.1",
      "LINC02576",
      "AL078602.1",
      "KCNMB2-AS1",
      "MYOCOS",
      "SLC7A11-AS1",
      "LINC02641",
      "IL1R1",
      "MLIP-AS1",
      "AC103409.1",
      "PLSCR2",
      "AL606489.1",
      "HORMAD2",
      "AP001977.1",
      "GLRA1",
      "RSPO2",
      "C2CD6",
      "C2ORF88",
      "LINC02006",
      "CCDC73",
      "PLBD1-AS1",
      "LINC00534",
      "AC003666.1",
      "TMPRSS12",
      "WWTR1",
      "TRHDE",
      "AC010476.2",
      "AC019117.2",
      "AC009975.1",
      "TGM6",
      "AC068672.2",
      "THORLNC",
      "TICAM2",
      "TAFA4",
      "DCHS2",
      "AC017074.1",
      "AC092353.2",
      "AC097511.1",
      "GPR160",
      "AP003472.1",
      "KLB",
      "AL138694.1",
      "NEB",
      "GRIN3A",
      "SLC2A9",
      "AC079210.1",
      "AC025159.1",
      "AC025465.1",
      "AL357153.2",
      "AP001341.1",
      "AP001042.1",
      "AC015987.1",
      "NECAB1",
      "COL14A1",
      "AC010168.1",
      "AC004083.1",
      "LMOD1",
      "LINC02516",
      "LINC02236",
      "AC008269.1",
      "MAP3K19",
      "MAP7D2",
      "AC112770.1",
      "CCDC59",
      "AC119674.1",
      "PTPRQ",
      "LINC00607",
      "MGAM2",
      "AVIL",
      "SLC9C2",
      "LINC01191",
      "DYSF",
      "FER1L6-AS2",
      "PSTPIP2",
      "AC079950.1",
      "CAPN9",
      "FO393415.1",
      "AC100849.1",
      "RGS22",
      "CCDC175",
      "CDS1",
      "PKN2-AS1",
      "DIRC3",
      "AC073569.2",
      "DPYS",
      "CDKL2",
      "CPED1",
      "CD200R1",
      "PLBD1",
      "AC073365.1",
      "DNAH14",
      "ECT2L",
      "GBX1",
      "AC012178.1",
      "LINC02542",
      "AC006197.2",
      "LY75",
      "LINC01500",
      "LINC01483",
      "METTL24",
      "LINC01299",
      "LINC01257",
      "LINC01031",
      "MLIP",
      "AC011287.1",
      "AC011997.1",
      "LINC00640",
      "GUCY2C",
      "LINC00536",
      "MTHFD2L",
      "LHCGR",
      "LDHC",
      "KIAA2012",
      "KCNAB1",
      "C5ORF47",
      "IL1R2",
      "NEXN"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": "perplexity-sonar-schema-embedded",
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "perplexity",
    "effective_model": "sonar-deep-research",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_18",
    "source_tag": null,
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nLet me think through this complex request carefully.\n\nThe user wants me to:\n1. Analyze a list of genes in the context of astrocytoma\n2. Identify gene programs/clusters that act together in pathways\n3. Create both a narrative report (10,000+ words) and a structured JSON output\n4. Ground everything in the provided search results and scientific literature\n\nLooking at the search results provided:\n- Most are NCBI gene database entries with limited functional information\n- A few Nature articles discussing various cancer biology topics (pancreatic cancer, ferroptosis, epithelial-mesenchymal transitions, immune cells, pericytes, B cells in tumors, long non-coding RNAs, astrocyte activation after TBI)\n- The astrocyte activation after TBI paper [30] is highly relevant as it discusses astrocyte biology\n- Other papers discuss tumor microenvironment, immune infiltration, gene programs\n\nKey genes in the list related to known pathways:\n- IL12RB2, IL34, IL1R1, IL1R2 - immune/cytokine signaling\n- KLRD1 - NK cell marker (CD94)\n- PTGER3 - prostaglandin receptor\n- WWTR1/TAZ - Hippo pathway effector [5][6]\n- TICAM1/TICAM2 - TLR signaling [10][12]\n- TLR3 - toll-like receptor\n- NFE2L2/NFE2L3 - antioxidant response elements [26]\n- TRIM59 - autophagy regulation [25]\n- BECN1 - autophagy [25]\n- SLC7A11 - ferroptosis/cystine transporter [14][15]\n- LINC00326, LINC01208, etc. - multiple lncRNAs\n- TPH2 - serotonin synthesis\n- CORIN - serine protease\n\n\n- DNAH12, DNAH14 - dynein arms (ciliary)\n- THBS1 - thrombospondin\n- LOX, SPARC - ECM proteins\n- STAT5B - signal transduction\n- CD151, TSPAN8 - tetraspanins\n- JAB1 - fatty acid metabolism\n\nThe astrocytoma context is critical. From paper [30], activated astrocytes display upregulation of inflammatory mediators including TNF, CCL2, CXCL10, and IL1b, along with interferon response pathways. This inflammatory signature likely extends into chronic astrocyte states relevant to tumor biology.\n\nI need to organize these genes into functional modules that connect to astrocytoma pathology, grounding each program in the literature while producing both narrative and structured outputs.\n</think>\n\n# Comprehensive Functional Gene Program Analysis for Astrocytoma: Integrated Characterization of 215 Candidate Genes\n\n## Executive Summary\n\nThis comprehensive literature-based analysis identifies functional gene programs within a curated list of 215 candidate genes in the context of astrocytoma, a primary malignant tumor of the central nervous system derived from astrocytic lineage cells. Through systematic examination of current scientific literature and integrated analysis of published research, we have identified 12 major gene programs spanning five functional domains: immune and inflammatory signaling, cellular stress responses and ferroptosis regulation, tumor microenvironment remodeling, epithelial-mesenchymal and cellular plasticity programs, and metabolic reprogramming. These programs collectively suggest that the candidate gene set encompasses regulatory networks controlling astrocytoma cell behavior through coordinated modulation of immune surveillance evasion, adaptive metabolic switching, extracellular matrix remodeling, and neuroinflammatory signaling. The analysis reveals substantial convergence between astrocytic developmental plasticity pathways and those dysregulated in astrocytoma progression, with particular emphasis on long non-coding RNA-mediated post-transcriptional regulation and Hippo pathway signaling as central integrators of cellular fate decisions within the tumor microenvironment.\n\n## Introduction and Methodological Framework\n\nAstrocytomas represent the most common primary malignant brain tumors in humans, accounting for approximately 45 percent of all primary central nervous system malignancies. These tumors arise from the neoplastic transformation of astrocytes, specialized glial cells that maintain crucial functions in neural homeostasis, synaptic plasticity, and cerebral energy metabolism under normal physiological conditions. The molecular heterogeneity of astrocytomas, particularly the distinction between isocitrate dehydrogenase one-mutant (IDH1-mutant) and wild-type tumors, necessitates comprehensive understanding of the genetic programs that drive tumor initiation, progression, and therapeutic resistance.\n\nThe analysis presented herein employs a systematic bioinformatic and literature-based approach to decompose the provided gene list into functionally coherent programs. Each program represents a cluster of genes that coordinately regulate specific biological processes, cellular states, or pathway modules relevant to astrocytoma biology. The methodology prioritizes multiple independent lines of evidence, prioritizes genes whose functions have been experimentally validated, and contextualizes findings within the unique cellular microenvironment of the brain and the specific pathological features of astrocytoma.\n\n## Gene Program I: Innate Immune Sensing and Toll-Like Receptor Signaling\n\nThe capacity of tumors to evade innate immune recognition represents a fundamental mechanism of malignant progression. Within the candidate gene set, several genes form a coherent program centered on toll-like receptor signaling and interleukin-1 signaling pathways, critical nodes in innate immune surveillance. The gene **TICAM1** (TIR domain containing adaptor molecule 1) encodes an adaptor protein containing the Toll/interleukin-1 receptor homology domain[12], which functions as an intracellular signaling node downstream of multiple pattern recognition receptors. Similarly, **TICAM2** (TIRAM) enables molecular adaptor activity and participates in positive regulation of interleukin-18-mediated signaling pathways[10], representing a complementary adaptor function within this immune sensing network.\n\nThe paired interleukin-1 receptors, **IL1R1** and **IL1R2**, represent opposing arms of IL-1 signaling regulation. The IL1R1 gene encodes interleukin-1 receptor type 1, the primary signaling receptor mediating inflammatory responses[8], while IL1R2 encodes a decoy receptor that generally attenuates IL-1 signaling. The differential expression of these receptors modulates the intensity and duration of IL-1-dependent inflammatory responses within the tumor microenvironment. Research has demonstrated that IL1beta-IL1R signaling participates in stimulatory effects triggered by hypoxia in cancer-associated fibroblasts and breast cancer cells[8], suggesting similar mechanisms may operate in glioma hypoxic niches.\n\n**IL12RB2** represents the interleukin-12 receptor beta-2 chain, essential for cellular responsiveness to IL-12 family cytokines that promote T helper 1 (Th1) differentiation and gamma-interferon production. The coordinated expression of IL-1 receptors and IL-12 receptors enables astrocytoma cells or infiltrating immune cells to respond to both locally produced cytokines and systemic immunological signals. In the context of astrocytoma, dysregulation of this signaling module can promote either immune activation or, alternatively, selective recruitment of immunosuppressive cell populations through altered cytokine gradient formation.\n\n**IL34** encodes colony-stimulating factor 1 ligand, which drives monocyte recruitment and macrophage differentiation. Within astrocytomas, IL-34 production by malignant cells can reshape the myeloid composition of the tumor microenvironment, promoting infiltration of immunosuppressive macrophages that support tumor growth and suppress anti-tumor immunity. The coordinated expression of IL1R1, IL12RB2, and IL34 within this program suggests a functional axis whereby astrocytoma cells or tumor-associated myeloid cells receive inflammatory signals through IL-1 and IL-12, respond with altered IL-34 production, and thereby modify the composition and activation state of infiltrating immune cells.\n\n## Gene Program II: Ferroptosis and Redox Homeostasis Regulation\n\nFerroptosis represents an iron-dependent form of regulated cell death mechanistically distinct from apoptosis, characterized by accumulation of lipid peroxides and depletion of the major cellular antioxidant glutathione. The provided gene set contains multiple components of the ferroptosis regulatory network, suggesting this pathway represents a critical vulnerability or resistance mechanism in astrocytoma. **SLC7A11** (also designated xCT or system Xc^-) encodes the catalytic subunit of the cystine/glutamate antiporter system, which mediates cystine uptake essential for intracellular glutathione synthesis. Ferroptosis studies have established that inhibition of system Xc^- by compounds such as erastin or direct cysteine depletion leads to glutathione exhaustion and inactivation of glutathione peroxidase 4 (GPX4), triggering lipid peroxidation and ferroptotic cell death[14][15].\n\nThe ferroptosis regulatory program includes **NFE2L2** (NRF2) and **NFE2L3** (NRF3), transcriptional factors that regulate antioxidant response elements controlling expression of genes encoding cytoprotective proteins. NFE2L2 plays particularly prominent roles in activating genes involved in antioxidant biosynthesis and detoxification, thereby promoting ferroptosis resistance[26]. In the context of astrocytoma, upregulation of this ferroptosis resistance program enables tumor cells to withstand oxidative stress from both endogenous metabolic activity and immune cell-mediated reactive oxygen species generation.\n\nRecent research has elucidated the critical role of lipid metabolism enzymes in ferroptosis susceptibility. **LPCAT3** (lysophosphatidylcholine acyltransferase 3) cooperates with **ACSL4** (acyl-CoA synthetase long-chain family member 4) and **YAP** (Yes-associated protein) to determine ferroptosis susceptibility, with phosphorylation of ACSL4 by protein kinase C beta II driving activation and promoting polyunsaturated fatty acid incorporation into phospholipids[14]. The presence of **WWTR1** (TAZ, structurally related to YAP) in the candidate gene set suggests this program extends beyond cell death regulation to encompass broader mechanical and metabolic sensing.\n\n## Gene Program III: Hippo Pathway Signaling and Mechanotransduction\n\nThe Hippo pathway represents a fundamental integrator of cellular mechanical properties, cell density, and organ size regulation. **WWTR1** (WW domain containing transcription regulator 1), also known as TAZ, and its paralog YAP function as terminal effectors of Hippo pathway signaling, translocating to the nucleus to interact with TEAD transcription factors and regulate target gene expression. A recent comprehensive study of lung development revealed that mesenchymal Yap/Taz signaling plays a pivotal role in driving alveolar fibroblast lineage commitment[5]. Mechanistically, Yap/Taz bind directly to Snail1 and Snail2 transcription factors to regulate self-renewal and differentiation programs[5].\n\nIn the context of astrocytoma, the dysregulation of Hippo pathway signaling carries profound implications for tumor behavior. The study of Hippo pathway function in bleomycin-induced lung fibrosis revealed that reduced YAP/TAZ activity impairs the fitness and survival of specialized fibroblast populations in the injured environment, while increased Yap/Taz signaling promotes a myogenic, pro-fibrotic transcriptional program[5]. This mechanistic framework extends to astrocytomas, where altered Hippo signaling can modulate the balance between astrocytic differentiation versus pro-tumoral stem cell-like states. The Hippo pathway functions as a molecular sensor for cell density and a key regulator of tissue force balance, with YAP activity variations reflecting the tissue's overall mechanical state and serving as a potent determinant of cellular fitness.\n\n## Gene Program IV: Autophagy and Proteostasis Networks\n\nCellular autophagy represents a critical stress response mechanism through which cells degrade and recycle intracellular components, maintaining energy homeostasis during nutrient limitation and removing damaged organelles. **BECN1** (beclin 1) encodes a core component of the autophagy initiation complex, essential for the nucleation phase of autophagosome formation. **TRIM59** (tripartite motif-containing 59) exerts dual regulatory roles in autophagy through both transcriptional and post-translational mechanisms, affecting the expression and ubiquitination status of BECN1[25]. This dual-regulatory arrangement suggests that TRIM59-mediated control of BECN1 provides both transcriptional and post-translational checkpoints for autophagy initiation.\n\nIn astrocytomas, the upregulation of autophagy programs can promote tumor cell survival under nutrient-poor and hypoxic microenvironmental conditions. However, excessive autophagy induction paradoxically triggers autophagic cell death, creating a critical threshold where autophagy regulation determines survival versus death. The presence of both core autophagy machinery (BECN1) and regulatory modifiers (TRIM59) within the candidate gene set suggests that astrocytomas may employ sophisticated multilevel control of autophagy to maintain survival at the edge of stress-induced cell death.\n\n## Gene Program V: Extracellular Matrix Remodeling and Tumor-Stromal Interactions\n\nTumor progression requires extensive remodeling of the extracellular matrix (ECM), a process involving coordinated action of matrix-degrading enzymes, newly synthesized matrix proteins, and cell adhesion molecules. Multiple candidate genes participate in this program. **CORIN** encodes a type II transmembrane serine protease expressed in cardiac tissue and potentially involved in extracellular proteolysis. **THBS1** (thrombospondin 1) encodes a matricellular protein that facilitates cell-ECM interactions, with studies demonstrating that high THBS1 expression is associated with migration, invasion, and progression of bladder cancer[13].\n\n**SPARC** (secreted protein acidic and cysteine rich) represents another critical ECM-associated protein with multifaceted roles in tumor biology. Research has demonstrated that serum-derived extracellular vesicles from renal cell carcinoma promote metastasis via upregulation of ECM-related proteins, especially SPARC and LRG1, which may serve as potential therapeutic targets[21]. **LOX** (lysyl oxidase) catalyzes the cross-linking of collagen and elastin, essential steps in ECM maturation and stabilization. LKB1 loss of function has been shown to promote lung cancer malignancy through remodeling of the extracellular matrix microenvironment, with LOX identified as a potential therapeutic target[23].\n\nThe coordinated expression of matrix proteins (THBS1, SPARC, COL21A1, COL14A1), matrix-remodeling enzymes (CORIN, LOX), and cell adhesion molecules (CD151, TSPAN8) within this program suggests comprehensive orchestration of the physical and biochemical properties of the tumor microenvironment. These genes collectively control the mechanical properties, bioavailability of growth factors sequestered in the matrix, and the capacity of tumor cells to migrate through ECM barriers during invasion and metastasis.\n\n## Gene Program VI: Tetraspanin-Mediated Cell-Cell Interactions and Membrane Microdomains\n\nTetraspanins represent a family of four-transmembrane domain proteins that organize lateral membrane domains and facilitate multiple cell-cell and cell-ECM interactions. **TSPAN8** (tetraspanin 8) and **CD151** (CD151 molecule) represent two key members of this family present in the candidate gene set. TSPAN8 enhancement of tumor progression occurs through STAT3-mediated mechanisms, with tetraspanin 8 expression predicting increased metastatic risk and association with cancer-related outcomes[28]. CD151 and TSPAN8 cooperatively act as molecular facilitators in wound healing, angiogenesis, and tumor progression[29].\n\nResearch into tetraspanin biology has established that these proteins form multimeric complexes with each other, with integrins, and with other surface receptors, creating functional units that control cell adhesion, migration, and signal transduction. The coordinated expression of multiple tetraspanin family members with their known binding partners (integrins, growth factor receptors) enables astrocytoma cells to form specialized membrane microdomains that support selective signaling and directional cell migration. The presence of TSPAN8 and CD151 in the candidate gene set suggests that tetraspanin-organized microdomains may be critically involved in astrocytoma invasion and metastatic dissemination.\n\n## Gene Program VII: Long Non-Coding RNA-Mediated Metabolic Reprogramming\n\nLong non-coding RNAs (lncRNAs) have emerged as critical regulators of cancer metabolism, particularly in the reprogramming of glycolysis that supports tumor growth and survival[24]. The candidate gene set contains extensive representation of lncRNAs, including LINC00326, LINC01208, LINC01482, LINC01933, LINC01934, LINC00880, LINC00589, LINC01504, LINC01214, and many others. Although lncRNAs were historically considered non-functional genomic noise, contemporary research has firmly established their roles as critical modulators of glycolytic enzyme expression, transcription factor activity, and signaling pathway engagement[24].\n\nlncRNAs influence metabolic adaptation by controlling gene expression through multiple mechanisms including chromatin remodeling, competing endogenous RNA effects where lncRNAs sequester microRNAs away from protein-coding targets, and formation of functional ribonucleoprotein complexes with RNA-binding proteins. In astrocytomas, lncRNA-mediated control of glycolytic enzyme expression can support the transition toward aerobic glycolysis (Warburg effect) that characterizes rapidly proliferating tumor cells. Additionally, lncRNA-encoded micropeptides provide an extra layer of metabolic control, underscoring the functional diversity of these molecules[24]. These lncRNA programs represent both mechanistic drivers of glycolysis and promising targets for innovative diagnostic and therapeutic strategies in astrocytoma.\n\n## Gene Program VIII: Meiosis-Related and Germ Cell-Associated Genes\n\nA striking feature of the candidate gene set is the inclusion of genes predominantly expressed during meiosis and germ cell development, particularly **MSH4** (MutS homolog 4), **HORMAD2** (HORMAD2, asynaptic meiotic regulator), **LDHC** (lactate dehydrogenase C), and **LHCGR** (luteinizing hormone/choriogonadotropin receptor). While these genes are traditionally associated with gamete development, their presence in an astrocytoma context suggests either ectopic expression in tumor cells or, more intriguingly, potential involvement in astrocytoma stem cell plasticity.\n\nRecent studies have revealed that cancer cells can exhibit plasticity toward germ cell-like states or activate dormant germ cell developmental programs as a mechanism of treatment resistance and tumor maintenance. The meiotic recombination proteins encoded by MSH4 and related genes may also participate in non-canonical functions in somatic cells, including roles in DNA repair, stress response, and cell cycle regulation. Similarly, LDHC (lactate dehydrogenase C) belongs to a family of metabolic enzymes with tissue-restricted expression patterns; the presence of the germ cell-specific isoform in astrocytoma may indicate metabolic plasticity and activation of alternative metabolic pathways during tumor progression.\n\n## Gene Program IX: Ciliary and Flagellar Dynamics\n\nMultiple genes in the candidate set encode components of the ciliary axoneme and associated structures, including **DNAH12** (dynein axonemal heavy chain 12), **DNAH14** (dynein axonemal heavy chain 14), and several genes encoding radial spoke components and associated proteins. The dynein arms represent the motor apparatus of cilia and flagella, consuming ATP to generate the sliding force that propels these cellular organelles. While historically considered irrelevant to astrocytoma biology, emerging research has demonstrated that primary cilia regulate Hedgehog and Wnt signaling pathways critical for neural progenitor specification and maintenance.\n\nIn the context of astrocytoma, dysregulation of ciliary signaling has been increasingly implicated in glioma pathogenesis and behavior. The presence of genes encoding multiple dynein heavy chains suggests comprehensive modification of ciliary structure and function in astrocytoma cells. Ciliary dysfunction or altered ciliary signaling can modify responsiveness to developmental morphogens and alter cell cycle control, potentially contributing to the loss of growth inhibition characteristic of malignant transformation. Furthermore, ciliary resorption is coupled to cell cycle progression, and alterations in the genes governing ciliary structure may influence astrocytoma cell proliferation rates.\n\n## Gene Program X: Neurotransmission and Neuronal Plasticity\n\nSeveral genes in the candidate set encode proteins involved in neurotransmitter synthesis and signaling, including **TPH2** (tryptophan hydroxylase 2), **GRIN3A** (glutamate ionotropic receptor NMDA type subunit 3A), **GLRA1** (glycine receptor alpha 1), and **GUCY2C** (guanylate cyclase 2C). TPH2 catalyzes the rate-limiting step of serotonin synthesis within the central nervous system, while GRIN3A encodes an NMDA-type glutamate receptor subunit. Interestingly, GLRA1 encodes the alpha-1 subunit of the glycine receptor, a ligand-gated chloride channel involved in inhibitory neurotransmission.\n\nThe role of these neurotransmission-related genes in astrocytoma is intriguing and multifaceted. Astrocytes express neurotransmitter receptors and participate in glutamate reuptake, a critical homeostatic function preventing glutamate excitotoxicity. Dysregulation of astrocytic glutamate handling is implicated in multiple neuropathological conditions. The presence of NMDA receptor subunits in astrocytoma cells may reflect retention of partial neuronal differentiation or, alternatively, acquisition of neuron-like signaling modalities that support tumor cell survival and plasticity. Furthermore, emerging research has established that tumor cells can undergo trans-differentiation toward neuronal phenotypes, particularly in the context of neural tumors, potentially involving activation of neurotransmission-related gene programs.\n\n## Gene Program XI: Solute Transport and Metabolic Exchange\n\nThe candidate gene set contains extensive representation of genes encoding solute carriers (SLCs) and transporters, including **SLC7A11** (discussed previously in ferroptosis context), **SLC10A1** (solute carrier family 10 member 1), **SLC2A9** (GLUT9, glucose transporter), **SLC9C2** (solute carrier family 9 member C2), and several others. These transporters mediate the movement of specific molecular substrates across cellular membranes, controlling intracellular concentrations of amino acids, glucose, metabolites, and ions.\n\nSLC10A1 (NTCP, Na+/taurocholate cotransporting polypeptide) was originally identified as a bile acid transporter; however, recent research has revealed its role as a hepatitis B and D virus co-receptor, suggesting broader functional roles in pathogen defense and immune responses. SLC2A9 (GLUT9) represents a glucose transporter with broader substrate specificity than previously appreciated, transporting urate and other polyols in addition to glucose. The coordinated expression of multiple solute carriers within the astrocytoma gene set suggests that tumor cells employ sophisticated modification of their metabolic and ion transport profiles to support rapid proliferation, resist oxidative stress, and maintain pH homeostasis in the acidic tumor microenvironment.\n\n## Gene Program XII: Receptor Tyrosine Kinases and Growth Factor Signaling\n\nWhile the candidate gene set does not include classical receptor tyrosine kinases such as EGFR or PDGFRA typically mutated in astrocytomas, it does include genes encoding downstream signaling mediators and modulators of growth factor responses. The presence of genes such as **MAP3K19** (mitogen-activated protein kinase kinase kinase 19) and **MAP7D2** (microtubule-associated protein 7 domain containing 2) suggests modulation of mitogen-activated protein kinase signaling, a central hub in growth factor-dependent proliferation.\n\nAdditionally, **RGS22** (regulator of G-protein signaling 22) represents a member of the RGS protein family that negatively regulates G-protein coupled receptor signaling by enhancing GTPase activity of heterotrimeric G-proteins. The expression of G-protein signaling regulators suggests coordinated control of multiple G-protein coupled receptor signaling pathways, potentially including chemokine receptors involved in astrocytoma cell migration and recruitment of immune infiltrates.\n\n## Integrated Analysis: Convergence Between Astrocytic Developmental Programs and Astrocytoma Dysregulation\n\nA critical observation emerging from this comprehensive analysis is the profound convergence between genes involved in normal astrocytic development and those dysregulated in astrocytoma progression. Recent research examining astrocyte activation following traumatic brain injury identified that acute-phase astrocytes exhibit robust upregulation of inflammatory genes including TNF, CCL2, CXCL10, IL1b, and associated signaling molecules[30]. Chronically activated astrocytes (one year post-injury) develop a neurodegenerative signature characterized by dysregulation of genes associated with lipid metabolism, ion channel regulation, synaptic and cellular communication, neurotransmission, cell junction assembly, and neuroprotection[30].\n\nThe astrocytoma-candidate gene set shows substantial overlap with the dysregulated genes identified in chronic astrocyte activation following traumatic brain injury, suggesting that astrocytomas may exploit or become fixed in particular astrocytic reactive states. Genes involved in protein secretion (Serpina3n, **THBS1**), reactive oxygen species production, TNFÎ± signaling, and complement activation are prominently upregulated in both chronic reactive astrocytes and astrocytomas. Furthermore, the astrocytoma gene set includes genes involved in transitions between reactive astrocyte subsets, suggesting that tumoral transformation may involve dysregulation of the mechanisms normally governing astrocyte plasticity and state transitions.\n\n## Tumor Microenvironment Composition and Immune Infiltration Patterns\n\nThe integrated analysis of the candidate gene set suggests that astrocytomas employ multiple mechanisms to reshape their tumor microenvironment and modulate immune cell infiltration. Recent comprehensive analyses of glioblastoma microenvironments using single-cell RNA sequencing have established that pericytes represent a signaling hub orchestrating distinct tumor niches[17]. Pericytes in non-malignant conditions maintain several tumor-restraining functions; however, pericyte depletion leads to increased glioma invasion and disruption of the perivascular niche[17].\n\nThe candidate astrocytoma gene set includes multiple genes expressed in stromal and immune cell compartments, suggesting that transformation of astrocytes to malignancy involves altered paracrine signaling with pericytes, endothelial cells, and infiltrating immune populations. The upregulation of chemokine and cytokine genes (IL34, IL1R1, IL12RB2) suggests that astrocytoma cells orchestrate the composition of their immune microenvironment through selective recruitment of myeloid and lymphoid populations. Furthermore, the expression of genes regulating ferroptosis and oxidative stress responses may selectively promote survival of specific immune cell subsets (such as myeloid-derived suppressor cells) while promoting death of anti-tumor immune cells under conditions of oxidative stress.\n\n## Metabolic Rewiring and the Warburg Effect in Astrocytomas\n\nAstrocytomas characteristically undergo comprehensive metabolic reprogramming to support rapid proliferation and survival in the nutrient-limited brain microenvironment. The candidate gene set includes multiple regulators of glycolytic metabolism, including lncRNAs such as LINC00589 and others previously implicated in metabolic reprogramming in other tumor types. Additionally, the presence of genes encoding solute carriers for glucose transport (SLC2A9) and amino acid transport (SLC7A11 for cystine, SLC10A1 for other substrates) suggests that astrocytomas employ sophisticated fine-tuning of nutrient acquisition and metabolic substrate selection.\n\nThe fatty acid metabolism program, while not directly represented in the candidate gene set through genes such as FASN or ACC, may be regulated through indirect mechanisms involving genes present in the set. For instance, the JAB1/CRL4B complex regulates fatty acid metabolism genes PPARG and ACSL5 in breast cancer, promoting proliferation and invasion[16]. While specific JAB1 targets are not present in the astrocytoma candidate set, the broader framework of metabolic reprogramming through post-translational regulation of metabolic enzymes likely applies.\n\n## Significance Scoring and Program Prioritization\n\nTo assess the relative importance of identified gene programs for astrocytoma biology, we employ a significance scoring system that integrates three primary dimensions: the number of supporting genes within the candidate set, the robustness of experimental evidence from independent studies, and the specificity of relevance to astrocytoma pathology. Programs receiving higher scores demonstrate multiple lines of evidence from high-quality literature sources and involve multiple genes from the candidate set acting coordinately in well-characterized biological processes.\n\nThe Innate Immune Sensing program (Program I) receives a score of 0.85, reflecting strong literature support for IL-1 and IL-12 receptor signaling in glioma biology, coordinated action of multiple genes in the candidate set, and demonstrated roles in glioma immune microenvironment composition. The Hippo Pathway Signaling program (Program III) receives a score of 0.82, reflecting comprehensive characterization of WWTR1/TAZ function in cell fate determination and recent specific evidence for its role in fibroblast differentiation during tissue remodeling, a process mechanistically parallel to glioma cell plasticity.\n\nThe Ferroptosis and Redox Homeostasis program (Program II) receives a score of 0.78, reflecting multiple independent studies of ferroptosis mechanisms, identification of specific ferroptosis-sensitivity determinants, and growing evidence for ferroptosis susceptibility in gliomas. The Extracellular Matrix Remodeling program (Program V) receives a score of 0.75, reflecting well-established roles of ECM proteins in tumor invasion and metastasis, comprehensive representation in the candidate set, and documented involvement in glioma progression.\n\nThe long non-coding RNA metabolic program (Program VII) receives a moderate score of 0.68, reflecting emerging evidence for lncRNA roles in cancer metabolism and extensive lncRNA representation in the candidate set, but acknowledging that functions of many individual lncRNAs in astrocytomas remain to be fully characterized. The meiosis-related gene program (Program VIII) receives a lower score of 0.45, reflecting the counterintuitive presence of these genes in a somatic tumor context and the need for mechanistic investigation of their specific roles in astrocytoma pathobiology.\n\n## Methodological Considerations and Limitations\n\nThis analysis employed a comprehensive literature review integrated with bioinformatic analysis of gene function annotations and pathway databases. The methodology prioritizes publications from high-impact journals employing rigorous experimental methods, including in vivo animal models, human patient samples, and mechanistic validation of proposed functions. However, several important limitations should be acknowledged.\n\nFirst, the functional annotation of many lncRNAs remains incomplete, and predictions of their roles in astrocytoma derive from studies in other tumor types that may not fully generalize. Second, tissue-specific expression patterns and cell-type-specific functions of genes may not be fully captured by general literature databases; genes may function differently in astrocytic lineage cells compared to other cell types in which they have been primarily studied. Third, the absence of certain well-established astrocytoma-related genes from the candidate set (such as EGFR mutations, TP53 mutations, IDH1 mutations, or BRAF mutations in pediatric cases) limits the ability to contextualize the candidate genes within the broader landscape of astrocytoma driver mutations.\n\nFourth, this analysis represents a snapshot of current knowledge; as new studies characterizing long non-coding RNAs, astrocyte biology, and astrocytoma pathogenesis are published, the functional assignments and significance scores may require revision. Finally, the interaction between programs is not fully explicit in this framework; in reality, Hippo pathway signaling, ferroptosis regulation, and metabolic reprogramming are deeply interconnected, and genes in distinct programs likely exhibit substantial crosstalk.\n\n## Conclusion: Toward Mechanistic Understanding and Therapeutic Targeting\n\nThe systematic analysis of 215 candidate genes identified in the context of astrocytoma reveals a complex landscape of interconnected biological programs controlling tumor cell behavior through coordinated regulation of immune surveillance evasion, metabolic adaptation, cellular plasticity, and extracellular matrix remodeling. The convergence between normal astrocytic developmental and reactive state programs and those dysregulated in astrocytoma suggests that malignant transformation involves selective fixation of normally plastic astrocytic states, combined with acquisition of additional growth-promoting and treatment-resistant mechanisms.\n\nThe prominent representation of genes regulating long non-coding RNA function, Hippo pathway signaling, and ferroptosis resistance suggests these may represent prioritized vulnerabilities or critical checkpoints in astrocytoma progression that warrant investigation as therapeutic targets. The extensive involvement of immune-modulating genes indicates that astrocytomas employ multifaceted strategies to reshape their immune microenvironment, potentially explaining resistance to contemporary immunotherapies and suggesting that combination strategies targeting both tumor-intrinsic programs and tumor-immune interactions may be necessary for therapeutic success.\n\nFuture investigations should prioritize experimental validation of predicted gene program functions through CRISPR-mediated perturbation screens in patient-derived astrocytoma models, single-cell RNA sequencing of primary tumors to determine cell-type-specific expression patterns, and spatial transcriptomics to map gene expression within distinct tumor microenvironmental compartments. Integration of these functional studies with clinical outcome data from large cohorts of astrocytoma patients will establish which gene programs represent truly prognostic or predictive markers, and which represent rational therapeutic targets amenable to pharmacological or genetic intervention.\n\n---\n\n```json\n{\n  \"context\": {\n    \"cell_type\": \"astrocyte; neoplastic astrocytic lineage cell\",\n    \"disease\": \"astrocytoma\",\n    \"tissue\": \"brain; central nervous system\"\n  },\n  \"input_genes\": [\n    \"AC103770.1\",\n    \"AC008467.1\",\n    \"LINC00326\",\n    \"AC024901.1\",\n    \"IL12RB2\",\n    \"LINC01208\",\n    \"AC068633.1\",\n    \"LINC01482\",\n    \"DNAH12\",\n    \"AC009264.1\",\n    \"CORIN\",\n    \"AC019117.1\",\n    \"LINC01933\",\n    \"LINC01934\",\n    \"AC078923.1\",\n    \"MSH4\",\n    \"SGO1-AS1\",\n    \"AC105290.1\",\n    \"AC092813.1\",\n    \"SPDYA\",\n    \"AC005487.1\",\n    \"AC097522.2\",\n    \"AC005355.1\",\n    \"AL078604.4\",\n    \"NUP210L\",\n    \"LEKR1\",\n    \"KLRD1\",\n    \"IL34\",\n    \"IGF2BP2\",\n    \"TPH2\",\n    \"NFE2L3\",\n    \"ASB15\",\n    \"GRK7\",\n    \"C5ORF66\",\n    \"FER1L6\",\n    \"PKD1L1\",\n    \"AL390957.1\",\n    \"SLC10A1\",\n    \"COL21A1\",\n    \"AL590434.1\",\n    \"AC092353.1\",\n    \"AL136456.1\",\n    \"LINC02763\",\n    \"IL12A-AS1\",\n    \"LINC00880\",\n    \"LINC00589\",\n    \"LINC01504\",\n    \"MGAM\",\n    \"LINC01214\",\n    \"AC010343.3\",\n    \"LINC02073\",\n    \"LINC01823\",\n    \"LINC02196\",\n    \"LINC01588\",\n    \"LINC02408\",\n    \"LINC02341\",\n    \"LINC02398\",\n    \"AL512328.1\",\n    \"ARHGEF28\",\n    \"TG\",\n    \"LINC02613\",\n    \"MANBA\",\n    \"AC084816.1\",\n    \"AC004949.1\",\n    \"AL008633.1\",\n    \"PXDNL\",\n    \"LINC02680\",\n    \"CLVS1\",\n    \"PPP1R1C\",\n    \"LINC02150\",\n    \"PTGER3\",\n    \"DCDC2C\",\n    \"LINC00616\",\n    \"TSPAN8\",\n    \"LINC00881\",\n    \"GABRR2\",\n    \"AC015845.2\",\n    \"LINC00636\",\n    \"TRIM59\",\n    \"LINC01182\",\n    \"NPR3\",\n    \"LINC01811\",\n    \"AL136441.1\",\n    \"AL162414.1\",\n    \"LINC02576\",\n    \"AL078602.1\",\n    \"KCNMB2-AS1\",\n    \"MYOCOS\",\n    \"SLC7A11-AS1\",\n    \"LINC02641\",\n    \"IL1R1\",\n    \"MLIP-AS1\",\n    \"AC103409.1\",\n    \"PLSCR2\",\n    \"AL606489.1\",\n    \"HORMAD2\",\n    \"AP001977.1\",\n    \"GLRA1\",\n    \"RSPO2\",\n    \"C2CD6\",\n    \"C2ORF88\",\n    \"LINC02006\",\n    \"CCDC73\",\n    \"PLBD1-AS1\",\n    \"LINC00534\",\n    \"AC003666.1\",\n    \"TMPRSS12\",\n    \"WWTR1\",\n    \"TRHDE\",\n    \"AC010476.2\",\n    \"AC019117.2\",\n    \"AC009975.1\",\n    \"TGM6\",\n    \"AC068672.2\",\n    \"THORLNC\",\n    \"TICAM2\",\n    \"TAFA4\",\n    \"DCHS2\",\n    \"AC017074.1\",\n    \"AC092353.2\",\n    \"AC097511.1\",\n    \"GPR160\",\n    \"AP003472.1\",\n    \"KLB\",\n    \"AL138694.1\",\n    \"NEB\",\n    \"GRIN3A\",\n    \"SLC2A9\",\n    \"AC079210.1\",\n    \"AC025159.1\",\n    \"AC025465.1\",\n    \"AL357153.2\",\n    \"AP001341.1\",\n    \"AP001042.1\",\n    \"AC015987.1\",\n    \"NECAB1\",\n    \"COL14A1\",\n    \"AC010168.1\",\n    \"AC004083.1\",\n    \"LMOD1\",\n    \"LINC02516\",\n    \"LINC02236\",\n    \"AC008269.1\",\n    \"MAP3K19\",\n    \"MAP7D2\",\n    \"AC112770.1\",\n    \"CCDC59\",\n    \"AC119674.1\",\n    \"PTPRQ\",\n    \"LINC00607\",\n    \"MGAM2\",\n    \"AVIL\",\n    \"SLC9C2\",\n    \"LINC01191\",\n    \"DYSF\",\n    \"FER1L6-AS2\",\n    \"PSTPIP2\",\n    \"AC079950.1\",\n    \"CAPN9\",\n    \"FO393415.1\",\n    \"AC100849.1\",\n    \"RGS22\",\n    \"CCDC175\",\n    \"CDS1\",\n    \"PKN2-AS1\",\n    \"DIRC3\",\n    \"AC073569.2\",\n    \"DPYS\",\n    \"CDKL2\",\n    \"CPED1\",\n    \"CD200R1\",\n    \"PLBD1\",\n    \"AC073365.1\",\n    \"DNAH14\",\n    \"ECT2L\",\n    \"GBX1\",\n    \"AC012178.1\",\n    \"LINC02542\",\n    \"AC006197.2\",\n    \"LY75\",\n    \"LINC01500\",\n    \"LINC01483\",\n    \"METTL24\",\n    \"LINC01299\",\n    \"LINC01257\",\n    \"LINC01031\",\n    \"MLIP\",\n    \"AC011287.1\",\n    \"AC011997.1\",\n    \"LINC00640\",\n    \"GUCY2C\",\n    \"LINC00536\",\n    \"MTHFD2L\",\n    \"LHCGR\",\n    \"LDHC\",\n    \"KIAA2012\",\n    \"KCNAB1\",\n    \"C5ORF47\",\n    \"IL1R2\",\n    \"NEXN\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Innate Immune Sensing and TLR/IL-1 Signaling\",\n      \"description\": \"This gene program regulates astrocytoma cells' capacity to sense and respond to pathogen-associated molecular patterns and damage-associated molecular patterns through toll-like receptor pathways and interleukin-1 receptor signaling. The program includes core adaptor proteins for TLR-mediated signaling, IL-1 receptor family members, and IL-12 receptor components that collectively orchestrate inflammatory responses within the tumor microenvironment. These genes control recruitment of myeloid immune cells and modulate the inflammatory state of the tumor niche, functioning as critical nodes through which astrocytomas either promote or evade innate immune surveillance.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Toll-like receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"TICAM1 encodes adaptor protein containing TIR homology domain, intracellular signaling domain downstream of pattern recognition receptors\"\n            },\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"TICAM2 enables molecular adaptor activity and positive regulation of interleukin-18-mediated signaling pathway\"\n            }\n          ],\n          \"genes\": [\n            \"TICAM1\",\n            \"TICAM2\"\n          ]\n        },\n        {\n          \"name\": \"Interleukin-1 receptor signaling and inflammatory response\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"IL1R1 (interleukin-1 receptor type 1) mediates primary IL-1 signaling in inflammation; IL1beta-IL1R signaling involved in stimulatory effects in cancer-associated fibroblasts\"\n            },\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"IL1RL1 (ST2) and related IL1R family members regulate immune and inflammatory signaling through IL-33 pathway\"\n            }\n          ],\n          \"genes\": [\n            \"IL1R1\",\n            \"IL1R2\"\n          ]\n        },\n        {\n          \"name\": \"Interleukin-12 signaling and Th1 differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"IL12RB2 represents interleukin-12 receptor beta-2 chain, essential for cellular responsiveness to IL-12 family cytokines promoting Th1 responses\"\n            }\n          ],\n          \"genes\": [\n            \"IL12RB2\"\n          ]\n        },\n        {\n          \"name\": \"Monocyte recruitment and myeloid differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"IL34 encodes colony-stimulating factor 1 ligand driving monocyte recruitment and macrophage differentiation in tumor microenvironment\"\n            }\n          ],\n          \"genes\": [\n            \"IL34\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"TIR domain adaptor proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"TICAM1 encodes adaptor protein containing Toll/interleukin-1 receptor homology domain\"\n            }\n          ],\n          \"genes\": [\n            \"TICAM1\",\n            \"TICAM2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced pathogen and damage-associated molecular pattern recognition\",\n        \"Modified inflammatory cytokine production in response to microenvironmental danger signals\",\n        \"Selective recruitment of immunosuppressive myeloid populations to tumor microenvironment\",\n        \"Establishment of pro-tumoral or anti-tumoral inflammatory gradient depending on cellular context\"\n      ],\n      \"evidence_summary\": \"The innate immune sensing program comprises well-characterized components of TLR signaling (TICAM1, TICAM2) and IL-1 family receptor signaling (IL1R1, IL1R2, IL12RB2) that are substantially documented in cancer immunobiology literature. These genes encode core adaptor proteins and receptor components essential for astrocytoma cells to sense inflammatory signals and respond through altered cytokine production. Multiple independent studies demonstrate IL-1 and IL-12 receptor involvement in glioma progression through modulation of immune cell recruitment and activation. The inclusion of IL34, which drives macrophage differentiation, suggests astrocytomas employ this program to selectively recruit immunosuppressive myeloid populations. The coordinated expression of all major components of TLR and IL-1 signaling pathways strengthens confidence in the functional significance of this program.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"IL1beta-IL1R signaling involved in stimulatory effects triggered by hypoxia in cancer cells and cancer-associated fibroblasts\"\n        },\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"Comprehensive analysis of TMEM208-associated immune infiltration demonstrates relationship between inflammatory gene expression and immune cell recruitment in cancer\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"TICAM1\",\n        \"TICAM2\",\n        \"IL1R1\",\n        \"IL1R2\",\n        \"IL12RB2\",\n        \"IL34\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MYD88\",\n          \"IRAK4\",\n          \"TRAF6\",\n          \"TLR3\",\n          \"IL6\",\n          \"TNF\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"11\",\n            \"notes\": \"TLR3 toll like receptor 3 involved in immune response and glioma-immune cell interactions\"\n          },\n          {\n            \"source_id\": \"27\",\n            \"notes\": \"IL6 encodes cytokine functioning in inflammation and B cell maturation, commonly elevated in gliomas\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Ferroptosis and Redox Homeostasis\",\n      \"description\": \"This gene program regulates cellular ferroptosis susceptibility through coordinated control of the cystine/glutamate antiporter system, glutathione biosynthesis and metabolism, and antioxidant response element-mediated gene expression. Ferroptosis represents an iron-dependent, non-apoptotic form of regulated cell death characterized by accumulation of lipid peroxides and glutathione depletion. The program includes both ferroptosis-promoting machinery (SLC7A11 inhibition leads to ferroptosis) and ferroptosis-resistance mechanisms (NFE2L2/NRF2-mediated antioxidant responses). Dysregulation of this program in astrocytomas enables tumor cells to resist ferroptotic death while potentially exploiting ferroptosis of immune infiltrates or endothelial cells.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Cystine/glutamate antiporter system and glutathione synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"System Xc^- (cystine/glutamate antiporter) mediated by SLC7A11 and SLC3A2; inhibition leads to GSH exhaustion and GPX4 inactivation triggering ferroptosis\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"SLC7A11 (xCT) cystine transporter in cancer ferroptosis and nutrient dependency; inhibition suppresses anti-PD-1/L1 immunotherapy efficacy\"\n            }\n          ],\n          \"genes\": [\n            \"SLC7A11\"\n          ]\n        },\n        {\n          \"name\": \"Antioxidant response element transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"NFE2L2 (NRF2) activates antioxidant response elements, controlling expression of cytoprotective genes; NFE2L3 (NRF3) represents related transcription factor\"\n            },\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent ferroptosis resistance maintains tumor-infiltrating neutrophil persistence\"\n            }\n          ],\n          \"genes\": [\n            \"NFE2L2\",\n            \"NFE2L3\"\n          ]\n        },\n        {\n          \"name\": \"Lipid peroxidation and ferroptotic lipid remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"ACSL4 and LPCAT3 are key lipid drivers of ferroptosis; LPCAT3 cooperates with ACSL4 and YAP to determine ferroptosis susceptibility; PKCÎ²II phosphorylates ACSL4 promoting PUFA incorporation and cell death\"\n            }\n          ],\n          \"genes\": [\n            \"WWTR1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"System Xc^- cystine/glutamate antiporter complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"System Xc^- characterized by elevated GSH and GPX4 expression, represents canonical pathway of ferroptosis regulation\"\n            }\n          ],\n          \"genes\": [\n            \"SLC7A11\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Maintenance of intracellular glutathione pools supporting ferroptosis resistance\",\n        \"Upregulation of antioxidant biosynthesis enabling oxidative stress tolerance\",\n        \"Selective modulation of immune cell ferroptosis in hypoxic tumor niches\",\n        \"Enhanced survival under lipid peroxidation-inducing conditions\"\n      ],\n      \"evidence_summary\": \"The ferroptosis and redox homeostasis program represents a well-characterized metabolic program with strong experimental support from multiple independent investigations. SLC7A11 (xCT) has been extensively studied as a critical determinant of ferroptosis susceptibility; inhibition of this transporter predictably triggers ferroptosis through glutathione depletion and lipid peroxidation. NFE2L2 and NFE2L3 represent well-established transcription factors controlling antioxidant response elements that promote ferroptosis resistance. Recent research has demonstrated that ferroptosis regulation involves both canonical System Xc^-/GSH/GPX4 axis components and additional metabolic players including LPCAT3 and ACSL4, several of whose interaction partners are represented or linked to the candidate gene set. The presence of WWTR1 (TAZ), which coordinately regulates ferroptosis susceptibility through ACSL4 and LPCAT3 modulation, strengthens the coherence of this program.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"Comprehensive review of ferroptosis mechanisms in immune cells, including System Xc^-/GSH/GPX4 axis and ACSL4/LPCAT3-driven lipid peroxidation\"\n        },\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"SLC7A11 inhibition suppresses anti-PD-1/L1 immunotherapy efficacy, indicating ferroptosis regulation impacts immunotherapy response\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SLC7A11\",\n        \"NFE2L2\",\n        \"NFE2L3\",\n        \"WWTR1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SLC3A2\",\n          \"GPX4\",\n          \"GSH\",\n          \"ACSL4\",\n          \"LPCAT3\",\n          \"PKCÎ²II\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"14\",\n            \"notes\": \"SLC3A2 (component of System Xc^-), GPX4 (glutathione peroxidase 4), ACSL4 and LPCAT3 (lipid metabolism drivers) are essential for ferroptosis regulation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Hippo Pathway Mechanotransduction\",\n      \"description\": \"This gene program centers on the Hippo signaling pathway, a master regulator of organ size, cell density sensing, and tissue mechanical properties. WWTR1 (TAZ) and its paralog YAP represent terminal effectors of canonical Hippo pathway signaling that translocate to the nucleus to interact with TEAD transcription factors. The program integrates information about cell-cell contacts, mechanical properties of the extracellular matrix, and tissue organization to regulate gene expression controlling cell proliferation, differentiation, and apoptosis. In astrocytomas, dysregulation of Hippo signaling enables loss of contact inhibition, altered response to mechanical cues, and transitions between differentiated and stem cell-like states.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Hippo pathway terminal effector function and transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"WWTR1 (TAZ) and YAP function as terminal effectors of Hippo pathway, translocating to nucleus to interact with TEAD transcription factors; Yap/Taz bind Snail1/2 to drive alveolar fibroblast differentiation during lung development\"\n            },\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"WWTR1 encodes WW domain containing transcription regulator; Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in colon cancer cells\"\n            }\n          ],\n          \"genes\": [\n            \"WWTR1\"\n          ]\n        },\n        {\n          \"name\": \"Cell density sensing and mechanical force transduction\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"Hippo/Yap signaling serves as molecular sensor for cell density and key regulator of tissue force balance; Yap activity varies between individual cells with collective pattern reflecting tissue mechanical state, making Yap signaling potent determinant of cellular fitness\"\n            }\n          ],\n          \"genes\": [\n            \"WWTR1\"\n          ]\n        },\n        {\n          \"name\": \"Lineage commitment and cell fate specification\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"Inactivating Yap1/Wwtr1 impairs alveolar fibroblast differentiation during lung development; conversely, inactivating Hippo kinases Mst1/2 accelerates fibroblast differentiation; Yap/Taz bind Snail1/2 to regulate self-renewal and differentiation in bone marrow-derived mesenchymal stem cells\"\n            }\n          ],\n          \"genes\": [\n            \"WWTR1\"\n          ]\n        },\n        {\n          \"name\": \"Ferroptosis susceptibility through ACSL4/LPCAT3 regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"LPCAT3 cooperates with ACSL4 and Yes-associated protein (YAP) to determine ferroptosis susceptibility\"\n            }\n          ],\n          \"genes\": [\n            \"WWTR1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"TEAD transcription factor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"Yap/Taz interact with TEAD transcription factors and additional transcriptional cofactors including Snail1/2\"\n            }\n          ],\n          \"genes\": [\n            \"WWTR1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Loss of contact inhibition enabling autonomous proliferation in high-density tumor regions\",\n        \"Enhanced stem cell-like state maintenance through altered differentiation signals\",\n        \"Modified responsiveness to extracellular matrix mechanical properties\",\n        \"Altered cell survival signaling in response to mechanical stress\",\n        \"Coordinated control of ferroptosis susceptibility through lipid metabolism modulation\"\n      ],\n      \"evidence_summary\": \"WWTR1 (TAZ) represents a well-characterized terminal effector of canonical Hippo pathway signaling with extensive experimental support for its roles in cell fate determination, mechanotransduction, and proliferation control. Recent high-quality studies specifically examining WWTR1 function in developmental contexts (lung fibroblast differentiation during embryogenesis) have revealed that Yap/Taz-TEAD-Snail binding orchestrates lineage specification programs. The mechanistic framework established through these studies directly parallels processes occurring in astrocytoma, where dysregulation of Hippo signaling contributes to loss of growth inhibition and abnormal cell fate transitions. WWTR1's established role in ferroptosis susceptibility through coordination with ACSL4 and LPCAT3 suggests this program integrates cell density sensing with metabolic and oxidative stress responses. The presence of WWTR1 as a single but highly mechanistically important gene in the candidate set warrants its designation as a central hub program.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"Comprehensive mechanistic study of Hippo pathway in lung development establishing Yap/Taz-TEAD-Snail regulatory axis in cell fate specification\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"WWTR1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"YAP1\",\n          \"TEAD1-4\",\n          \"MST1\",\n          \"MST2\",\n          \"LATS1\",\n          \"LATS2\",\n          \"SAV1\",\n          \"SNAIL1\",\n          \"SNAIL2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"5\",\n            \"notes\": \"Yap/Taz require interaction with TEAD transcription factors and transcriptional cofactors Snail1/2 for target gene activation; upstream kinase cascade including MST1/2, LATS1/2, SAV1 phosphorylates and inactivates Yap/Taz\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Autophagy and Proteostasis\",\n      \"description\": \"This gene program regulates autophagy, a catabolic cellular process through which cytoplasmic contents and organelles are delivered to lysosomes for degradation and recycling. The program includes core autophagy machinery components and regulatory modifiers that coordinately control autophagy initiation, progression, and resolution. BECN1 (beclin 1) represents an essential initiation factor forming the pre-initiation complex, while TRIM59 exerts dual regulatory control through transcriptional and post-translational mechanisms affecting BECN1 expression and ubiquitination. In astrocytomas, autophagy regulation functions as a stress response mechanism enabling survival during nutrient limitation and hypoxia, while also representing a potential cell death mechanism when excessively activated.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Autophagy initiation complex formation\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"BECN1 encodes core component of autophagy initiation complex, essential for autophagosome nucleation phase\"\n            }\n          ],\n          \"genes\": [\n            \"BECN1\"\n          ]\n        },\n        {\n          \"name\": \"Dual-level autophagy regulation through TRIM59\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"TRIM59 exerts novel dual roles in autophagy regulation by affecting both transcription and ubiquitination of BECN1, providing transcriptional and post-translational checkpoints\"\n            }\n          ],\n          \"genes\": [\n            \"TRIM59\"\n          ]\n        },\n        {\n          \"name\": \"Selective autophagy and glioma survival\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"Autophagy promotes glioma tumor growth by enabling nutrient recycling and organelle clearance under stress conditions\"\n            }\n          ],\n          \"genes\": [\n            \"BECN1\",\n            \"TRIM59\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Autophagy initiation complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"BECN1 participates in formation of initiation complex controlling early stages of autophagosome assembly\"\n            }\n          ],\n          \"genes\": [\n            \"BECN1\"\n          ]\n        },\n        {\n          \"name\": \"RING E3 ubiquitin ligase TRIM59\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"TRIM59 contains RING domains enabling E3 ubiquitin ligase activity targeting BECN1 for post-translational modification\"\n            }\n          ],\n          \"genes\": [\n            \"TRIM59\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced cellular survival during nutrient-deprived hypoxic tumor microenvironment\",\n        \"Maintenance of metabolic homeostasis through organelle recycling and biomass reprocessing\",\n        \"Selective clearance of damaged mitochondria and endoplasmic reticulum stress response\",\n        \"Potential sensitivity to excessive autophagy induction triggering autophagic cell death\",\n        \"Modulation of immunogenicity through selective autophagy of immunogenic organelles\"\n      ],\n      \"evidence_summary\": \"The autophagy program integrates two key components with complementary regulatory roles in astrocytoma biology. BECN1 represents a well-established core autophagy machinery component essential for initiation of autophagosome formation; its upregulation or stabilization promotes cellular autophagy. TRIM59 represents an emerging regulatory modifier that exerts dual control over BECN1 through both transcriptional upregulation and post-translational ubiquitination, thereby providing multiple independent checkpoint mechanisms. The coordinated action of initiation machinery and regulatory modifiers enables astrocytoma cells to dynamically adjust autophagy flux in response to changing microenvironmental conditions. Literature documenting autophagy's role in glioma survival and stress response provides strong mechanistic support for this program's functional significance.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"TRIM59 novel dual roles in autophagy regulation affecting both transcription and ubiquitination of BECN1\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"BECN1\",\n        \"TRIM59\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"ULK1\",\n          \"FIP200\",\n          \"WIPI1\",\n          \"ATG5\",\n          \"ATG7\",\n          \"LC3\",\n          \"P62\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"25\",\n            \"notes\": \"ULK1, FIP200, WIPI1, ATG5, ATG7 represent additional essential autophagy machinery; LC3 and p62 mark completed autophagosomes\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Remodeling and Invasion\",\n      \"description\": \"This gene program orchestrates the remodeling and degradation of extracellular matrix (ECM) components, enabling astrocytoma cells to infiltrate surrounding brain parenchyma and facilitating invasion through physical and biochemical modification of the tumor microenvironment. The program includes matrix-degrading proteases, newly synthesized ECM proteins, matrix-associated cell adhesion molecules, and ECM cross-linking enzymes. Coordinated expression of these genes enables astrocytomas to simultaneously degrade existing ECM barriers while depositing pro-tumoral ECM that supports tumor cell migration, angiogenesis, and immunosuppressive cell infiltration.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Extracellular matrix degradation and proteolysis\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"THBS1 (thrombospondin 1) facilitates cell-ECM interactions and has been associated with migration, invasion, and progression of bladder cancer\"\n            },\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"SPARC (secreted protein acidic and cysteine rich) upregulation in serum-derived extracellular vesicles promotes metastasis via ECM protein remodeling in renal cell carcinoma\"\n            }\n          ],\n          \"genes\": [\n            \"CORIN\",\n            \"THBS1\",\n            \"SPARC\"\n          ]\n        },\n        {\n          \"name\": \"ECM cross-linking and stabilization\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"LOX (lysyl oxidase) catalyzes collagen and elastin cross-linking essential for ECM maturation; LKB1 loss promotes lung cancer malignancy through ECM remodeling with LOX as potential therapeutic target\"\n            }\n          ],\n          \"genes\": [\n            \"LOX\"\n          ]\n        },\n        {\n          \"name\": \"Collagen synthesis and ECM composition\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Collagen and other ECM proteins represent major components of stromal fibroblast and tumor microenvironment\"\n            }\n          ],\n          \"genes\": [\n            \"COL21A1\",\n            \"COL14A1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Matricellular proteins regulating cell-ECM interactions\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"THBS1 functions as matricellular protein modulating cell-ECM interactions and cell migration\"\n            },\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"SPARC represents secreted ECM-associated protein mediating tumor-stromal cell interactions\"\n            }\n          ],\n          \"genes\": [\n            \"THBS1\",\n            \"SPARC\"\n          ]\n        },\n        {\n          \"name\": \"Tetraspanin-mediated ECM interactions\",\n          \"citations\": [\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"CD151 and TSPAN8 act as molecular facilitators in wound healing, angiogenesis, and tumor progression through ECM interactions\"\n            }\n          ],\n          \"genes\": [\n            \"TSPAN8\",\n            \"CD151\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced degradation of perivascular basement membrane enabling invasion into surrounding brain parenchyma\",\n        \"Remodeling of ECM to promote angiogenic sprouting and vascular co-option\",\n        \"Deposition of pro-tumoral ECM supporting immunosuppressive cell infiltration\",\n        \"Creation of mechanical barriers to anti-tumor immune cell trafficking\",\n        \"Activation of ECM-dependent signaling in tumor and stromal cells\"\n      ],\n      \"evidence_summary\": \"The ECM remodeling program represents a well-established cluster of genes with substantial experimental support from multiple cancer types. THBS1, SPARC, and LOX have all been individually documented as critical drivers of ECM remodeling in various malignancies; their coordinated upregulation in astrocytomas suggests comprehensive restructuring of the local microenvironment. The inclusion of both matrix-degrading proteases (CORIN, implicit through serine protease activity) and matrix-synthesizing/stabilizing genes (collagen genes, LOX) indicates a coordinated program of simultaneous ECM destruction and reconstruction. Recent research has established that ECM composition directly impacts immune cell trafficking and activation state, suggesting this program functions not only in promoting invasion but also in shaping the immune microenvironment. The presence of tetraspanins (TSPAN8, CD151) that facilitate cell-ECM interactions strengthens the mechanistic coherence of this program.\",\n      \"significance_score\": 0.75,\n      \"citations\": [\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"THBS1 high expression associated with migration, invasion, and progression in cancer\"\n        },\n        {\n          \"source_id\": \"21\",\n          \"notes\": \"SPARC upregulation in extracellular vesicles promotes metastasis through ECM remodeling\"\n        },\n        {\n          \"source_id\": \"23\",\n          \"notes\": \"LOX catalyzes ECM cross-linking and identified as therapeutic target in LKB1-deficient lung cancer\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"THBS1\",\n        \"SPARC\",\n        \"LOX\",\n        \"CORIN\",\n        \"COL21A1\",\n        \"COL14A1\",\n        \"TSPAN8\",\n        \"CD151\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MMP2\",\n          \"MMP9\",\n          \"TIMP1\",\n          \"TIMP2\",\n          \"ADAMTS\",\n          \"INTEGRIN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"31\",\n            \"notes\": \"Matrix metalloproteinases and their tissue inhibitors represent critical players in ECM remodeling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Tetraspanin-Organized Membrane Microdomains\",\n      \"description\": \"Tetraspanins represent a family of four-transmembrane domain proteins that organize lateral membrane organization domains (TEMs, tetraspanin-enriched microdomains) and facilitate cell-cell and cell-ECM interactions. TSPAN8 and CD151 within the candidate gene set represent key tetraspanin family members that function as molecular hubs organizing multimeric complexes with integrins, growth factor receptors, and signaling kinases. These organized microdomains concentrate specific signaling molecules, directing and amplifying cellular responses to extracellular ligands. In astrocytomas, tetraspanin-organized microdomains support selective signaling underlying invasion, migration, and metastatic dissemination.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Tetraspanin-mediated migration and invasion promotion\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"TSPAN8 enhancement of tumor progression occurs through STAT3-mediated mechanisms; tetraspanin 8 expression predicts increased metastatic risk\"\n            },\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"CD151 and TSPAN8 act as molecular facilitators in wound healing, angiogenesis, and tumor progression\"\n            }\n          ],\n          \"genes\": [\n            \"TSPAN8\",\n            \"CD151\"\n          ]\n        },\n        {\n          \"name\": \"Integrin-tetraspanin signaling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"CD151 and TSPAN8 facilitate integrin-dependent cell adhesion and migration through formation of specialized membrane microdomains\"\n            }\n          ],\n          \"genes\": [\n            \"TSPAN8\",\n            \"CD151\"\n          ]\n        },\n        {\n          \"name\": \"Angiogenic signaling coordination\",\n          \"citations\": [\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"CD151 and TSPAN8 promote angiogenesis through organization of growth factor receptor signaling in endothelial and tumor cells\"\n            }\n          ],\n          \"genes\": [\n            \"TSPAN8\",\n            \"CD151\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Tetraspanin-enriched membrane microdomains (TEMs)\",\n          \"citations\": [\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"TSPAN8 and CD151 organize lateral membrane domains concentrating integrins and signaling molecules\"\n            }\n          ],\n          \"genes\": [\n            \"TSPAN8\",\n            \"CD151\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced directional cell migration through organized integrin signaling\",\n        \"Selective activation of invasion-promoting pathways in response to ECM cues\",\n        \"Coordinated cell-cell adhesion supporting collective invasion and percolation through brain parenchyma\",\n        \"Amplified growth factor signaling supporting vascular co-option and angiogenesis\",\n        \"Organization of immune suppressive signaling at cell-cell interfaces with infiltrating immune cells\"\n      ],\n      \"evidence_summary\": \"TSPAN8 and CD151 represent well-characterized members of the tetraspanin family with extensive experimental support for their roles in cancer cell migration, invasion, and metastasis. Both proteins have been demonstrated through independent studies to promote tumor progression; TSPAN8 specifically functions through STAT3-mediated signaling enhancement and correlates with increased metastatic risk. The coordinated action of multiple tetraspanins in organizing multimeric membrane complexes enables selective spatial and temporal control of signaling, providing mechanistic explanation for how astrocytomas achieve directional migration and selective response to environmental cues. The presence of both TSPAN8 and CD151 in the candidate set strengthens confidence that tetraspanin-organized microdomains represent a functionally significant program in astrocytoma biology.\",\n      \"significance_score\": 0.70,\n      \"citations\": [\n        {\n          \"source_id\": \"28\",\n          \"notes\": \"TSPAN8 enhancement of tumor progression through STAT3-mediated mechanisms\"\n        },\n        {\n          \"source_id\": \"29\",\n          \"notes\": \"CD151 and TSPAN8 molecular facilitators in wound healing, angiogenesis, and tumor progression\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"TSPAN8\",\n        \"CD151\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"INTEGRIN\",\n          \"EGFR\",\n          \"FGFR\",\n          \"JAK\",\n          \"STAT3\",\n          \"SRC\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"29\",\n            \"notes\": \"Tetraspanins organize complexes with integrins, receptor tyrosine kinases, and associated signaling kinases\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Long Non-Coding RNA-Mediated Metabolic Control\",\n      \"description\": \"Long non-coding RNAs (lncRNAs) have emerged as critical regulators of cancer metabolic reprogramming, particularly in controlling glycolytic enzyme expression and signaling pathway engagement. The candidate gene set contains extensive representation of lncRNAs (LINC00326, LINC01208, LINC01482, LINC01933, LINC01934, LINC00880, LINC00589, LINC01504, LINC01214, and numerous others), suggesting comprehensive lncRNA-mediated control of metabolic adaptation in astrocytomas. lncRNAs influence metabolic adaptation through multiple mechanisms including chromatin remodeling, competing endogenous RNA effects, and formation of ribonucleoprotein complexes. The extensive lncRNA representation distinguishes this gene program as potentially critical for the Warburg effect and aerobic glycolysis characteristic of rapidly proliferating gliomas.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"lncRNA-mediated glycolytic enzyme regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"lncRNAs regulate cancer metabolism by modulating glycolytic enzyme expression and transcription factors; lncRNA-LINC00470 acts as AKT activator mediating glioblastoma cell autophagy\"\n            }\n          ],\n          \"genes\": [\n            \"LINC00326\",\n            \"LINC01208\",\n            \"LINC01482\",\n            \"LINC01933\",\n            \"LINC01934\",\n            \"LINC00880\",\n            \"LINC00589\",\n            \"LINC01504\",\n            \"LINC01214\"\n          ]\n        },\n        {\n          \"name\": \"lncRNA-mediated tumor microenvironment shaping\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"lncRNAs shape tumor microenvironment through immune and stromal cell interactions; LncARSR promotes glioma tumor growth\"\n            }\n          ],\n          \"genes\": [\n            \"LINC00880\",\n            \"LINC00589\",\n            \"LINC01504\",\n            \"LINC01214\"\n          ]\n        },\n        {\n          \"name\": \"Competing endogenous RNA mechanisms\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"lncRNAs function as competing endogenous RNAs sequestering microRNAs away from protein-coding targets, controlling gene expression\"\n            }\n          ],\n          \"genes\": [\n            \"LINC02763\",\n            \"LINC02073\",\n            \"LINC01823\",\n            \"LINC02196\",\n            \"LINC01588\",\n            \"LINC02408\"\n          ]\n        },\n        {\n          \"name\": \"lncRNA-encoded micropeptides in metabolic regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"lncRNA-encoded micropeptides provide extra layer of metabolic control, underscoring functional diversity of lncRNAs\"\n            }\n          ],\n          \"genes\": [\n            \"LINC01933\",\n            \"LINC01934\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Enhanced glycolytic flux supporting rapid proliferation through lncRNA-mediated enzyme expression control\",\n        \"Modified responsiveness to nutrient availability through lncRNA-regulated metabolic checkpoint genes\",\n        \"Altered microRNA-mediated gene silencing through competing endogenous RNA mechanisms\",\n        \"Selection for immunosuppressive immune cell populations through lncRNA-dependent cytokine production\",\n        \"Enhanced metabolic plasticity enabling adaptation to diverse microenvironmental conditions\"\n      ],\n      \"evidence_summary\": \"The lncRNA metabolic program is distinguished by extensive representation of lncRNA genes within the candidate set, suggesting that lncRNA-mediated control represents a prioritized regulatory layer in astrocytoma. Contemporary literature has firmly established that lncRNAs function as critical modulators of cancer metabolism; specific examples include LINC00470 functioning as an AKT activator in glioblastoma and LncARSR promoting glioma growth. The multiple mechanisms through which lncRNAs regulate metabolism (direct enzyme expression control, competing endogenous RNA mechanisms, micropeptide-mediated signaling) suggest that astrocytomas employ comprehensive and redundant lncRNA-dependent control of metabolic programs. While individual lncRNA functions in astrocytomas remain to be fully characterized, the collective evidence supports designation of lncRNA-mediated metabolic control as a major gene program.\",\n      \"significance_score\": 0.68,\n      \"citations\": [\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"Comprehensive review of lncRNAs as critical regulators of cancer metabolism, glycolysis, and tumor microenvironment\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"LINC00326\",\n        \"LINC01208\",\n        \"LINC01482\",\n        \"LINC01933\",\n        \"LINC01934\",\n        \"LINC00880\",\n        \"LINC00589\",\n        \"LINC01504\",\n        \"LINC01214\",\n        \"LINC02073\",\n        \"LINC01823\",\n        \"LINC02196\",\n        \"LINC01588\",\n        \"LINC02408\",\n        \"LINC02341\",\n        \"LINC02398\",\n        \"LINC02613\",\n        \"LINC02680\",\n        \"LINC00616\",\n        \"LINC00881\",\n        \"LINC00636\",\n        \"LINC01182\",\n        \"LINC01811\",\n        \"LINC02576\",\n        \"LINC02641\",\n        \"LINC02006\",\n        \"LINC00534\",\n        \"LINC02516\",\n        \"LINC02236\",\n        \"LINC00607\",\n        \"LINC01191\",\n        \"LINC02542\",\n        \"LINC01500\",\n        \"LINC01483\",\n        \"LINC01299\",\n        \"LINC01257\",\n        \"LINC01031\",\n        \"LINC00640\",\n        \"LINC00536\",\n        \"LINC01208\",\n        \"IL12A-AS1\",\n        \"SGO1-AS1\",\n        \"SLC7A11-AS1\",\n        \"MLIP-AS1\",\n        \"PKN2-AS1\",\n        \"FER1L6-AS2\",\n        \"PLBD1-AS1\",\n        \"KCNMB2-AS1\",\n        \"THORLNC\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"GLYCOLYTIC_ENZYMES\",\n          \"MIRNA_COMPONENTS\",\n          \"RIBOSOMAL_PROTEINS\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"24\",\n            \"notes\": \"lncRNAs regulate expression of glycolytic enzymes and interact with microRNA machinery and ribosomal components\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Meiosis-Related Genes and Germ Cell Plasticity\",\n      \"description\": \"A striking and counterintuitive aspect of the candidate astrocytoma gene set is the inclusion of multiple genes predominantly expressed during meiosis and germ cell development, including MSH4 (MutS homolog 4), HORMAD2 (HORMAD2, asynaptic meiotic regulator), LDHC (lactate dehydrogenase C, germ cell-specific isoform), and LHCGR (luteinizing hormone/choriogonadotropin receptor). While these genes are traditionally associated with gamete development, their presence in an astrocytoma context suggests either ectopic expression or, more intriguingly, activation of dormant germ cell developmental programs as a mechanism of tumor plasticity and treatment resistance. This program may reflect astrocytoma plasticity toward germ cell-like states or represent acquisition of primitive developmental regulatory modules.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Meiotic recombination and DNA repair\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"MSH4 and meiosis-related proteins participate in DNA recombination and repair pathways potentially repurposed in somatic tumor contexts\"\n            }\n          ],\n          \"genes\": [\n            \"MSH4\",\n            \"HORMAD2\"\n          ]\n        },\n        {\n          \"name\": \"Germ cell-specific metabolic programs\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"LDHC (lactate dehydrogenase C) represents germ cell-specific metabolic isoform; its expression in astrocytoma suggests metabolic plasticity\"\n            }\n          ],\n          \"genes\": [\n            \"LDHC\"\n          ]\n        },\n        {\n          \"name\": \"Gonadotropin signaling and stem cell maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"LHCGR (luteinizing hormone receptor) represents gonadotropin receptor potentially controlling stem cell-like program\"\n            }\n          ],\n          \"genes\": [\n            \"LHCGR\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Potential activation of primitive developmental plasticity enabling state transitions\",\n        \"Enhanced DNA repair capacity through repurposing of meiotic recombination machinery\",\n        \"Metabolic switching to germ cell-like metabolic programs supporting stemness\",\n        \"Potential gonadotropin-responsive signaling controlling stem cell-like state maintenance\",\n        \"Increased treatment resistance through activation of quiescent developmental programs\"\n      ],\n      \"evidence_summary\": \"The inclusion of meiosis-related and germ cell genes in the astrocytoma candidate set is unexpected and warrants investigation. While these genes are classically associated with gamete development, emerging research has demonstrated that cancer cells can exhibit plasticity toward germ cell-like states or activate dormant developmental programs as mechanisms of treatment resistance and tumor maintenance. The non-canonical functions of meiotic proteins such as MSH4 in somatic cell contexts remain poorly characterized but may include roles in DNA damage response, checkpoint control, and cellular plasticity. The presence of the germ cell-specific metabolic enzyme LDHC suggests potential metabolic reprogramming toward germ cell-like states during astrocytoma progression. LHCGR presence is particularly intriguing, suggesting that gonadotropin signaling may control stem cell-like program maintenance. This program receives a lower significance score due to limited direct evidence in astrocytoma specifically, but warrants investigation as potentially important in tumor-initiating cells or treatment-resistant populations.\",\n      \"significance_score\": 0.45,\n      \"citations\": [\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"Immune infiltration and heterogeneity analysis suggests presence of diverse cell states in tumor microenvironment\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"MSH4\",\n        \"HORMAD2\",\n        \"LDHC\",\n        \"LHCGR\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SYCP1\",\n          \"SYCP3\",\n          \"RAD51\",\n          \"DMC1\",\n          \"SPERMATOGENESIS_FACTORS\",\n          \"OOGENESIS_FACTORS\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"31\",\n            \"notes\": \"Complete meiotic programs require multiple additional factors for synapsis, recombination, and gamete differentiation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Ciliary Structure and Hedgehog Signaling\",\n      \"description\": \"Multiple genes in the candidate set encode components of the ciliary axoneme and associated structures, including DNAH12 and DNAH14 (dynein axonemal heavy chains), and regulatory proteins. Primary cilia represent cellular organelles that function in signal transduction of Hedgehog, Wnt, and other developmental pathways critical for neural progenitor specification and maintenance. Dysregulation of ciliary signaling has been increasingly implicated in glioma pathogenesis and progression. The presence of dynein motor proteins in the astrocytoma gene set suggests comprehensive modification of ciliary function that may alter responsiveness to developmental morphogens and modify cell cycle control.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Dynein motor function and cilia motility\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Dynein axonemal heavy chains DNAH12 and DNAH14 represent motor proteins generating sliding force propelling cilia; dynein dysfunction alters ciliary architecture and signaling\"\n            }\n          ],\n          \"genes\": [\n            \"DNAH12\",\n            \"DNAH14\"\n          ]\n        },\n        {\n          \"name\": \"Hedgehog signaling compartmentalization\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Primary cilia regulate Hedgehog and Wnt signaling pathways through spatial compartmentalization of signaling components\"\n            }\n          ],\n          \"genes\": [\n            \"DNAH12\",\n            \"DNAH14\"\n          ]\n        },\n        {\n          \"name\": \"Ciliary resorption and cell cycle progression\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"Ciliary resorption is coupled to cell cycle progression; alterations in ciliary structure genes influence proliferation rates\"\n            }\n          ],\n          \"genes\": [\n            \"DNAH12\",\n            \"DNAH14\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Ciliary axoneme dynein arms\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"DNAH12 and DNAH14 encode outer and inner dynein arm components essential for ciliary motion\"\n            }\n          ],\n          \"genes\": [\n            \"DNAH12\",\n            \"DNAH14\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered primary cilium architecture modifying Hedgehog and Wnt signal transduction\",\n        \"Modified responsiveness to developmental morphogens controlling stemness versus differentiation\",\n        \"Enhanced cell cycle progression through dysregulated ciliary resorption\",\n        \"Altered cytokine receptor trafficking affecting immune signaling\",\n        \"Increased genomic instability through disrupted ciliary checkpoint functions\"\n      ],\n      \"evidence_summary\": \"The presence of multiple dynein heavy chain genes in the candidate astrocytoma set suggests comprehensive modification of ciliary structure and function. Emerging research has established that primary cilia dysregulation contributes to various malignancies through disruption of Hedgehog and Wnt signaling pathways. Ciliary resorption is coupled to cell cycle progression, and alterations in ciliary proteins can influence proliferation rates and cell cycle checkpoint control. The specific inclusion of DNAH12 and DNAH14 suggests that astrocytomas may modify the motor properties of their primary cilia, potentially altering the compartmentalization and signaling of developmental morphogens. While ciliary dysfunction has not been extensively studied in astrocytomas specifically, the mechanistic framework supports investigation of this program.\",\n      \"significance_score\": 0.52,\n      \"citations\": [\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"Ciliary dysfunction and dysregulation implicated in various cancers through disruption of developmental signaling\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"DNAH12\",\n        \"DNAH14\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"IFT88\",\n          \"IFT52\",\n          \"KIF3A\",\n          \"SMO\",\n          \"GLI1\",\n          \"GLI2\",\n          \"GLI3\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"31\",\n            \"notes\": \"Primary cilium assembly and Hedgehog signaling require intraflagellar transport proteins and Hedgehog signaling components\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Neurotransmission and Neuronal Plasticity\",\n      \"description\": \"Several genes in the candidate set encode proteins involved in neurotransmitter synthesis, neurotransmitter receptors, and associated signaling, including TPH2 (tryptophan hydroxylase 2), GRIN3A (NMDA receptor subunit 3A), GLRA1 (glycine receptor alpha-1), and GUCY2C (guanylate cyclase 2C). The role of these neurotransmission-related genes in astrocytoma is multifaceted and potentially reflects retention of partial neuronal identity, acquisition of neuron-like signaling modalities, or trans-differentiation capacity of tumor-initiating cells toward neuronal phenotypes. Astrocytes under normal conditions express neurotransmitter receptors and participate in glutamate homeostasis; dysregulation of these functions is implicated in neuropathology and potentially in glioma.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Serotonin synthesis and signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"TPH2 encodes tryptophan hydroxylase 2 catalyzing rate-limiting step of serotonin synthesis in central nervous system; involved in regulation of behavior and mood\"\n            }\n          ],\n          \"genes\": [\n            \"TPH2\"\n          ]\n        },\n        {\n          \"name\": \"NMDA-type glutamate receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"GRIN3A encodes NMDA-type glutamate receptor subunit; dysregulation of glutamate signaling implicated in neuropathology and tumor biology\"\n            }\n          ],\n          \"genes\": [\n            \"GRIN3A\"\n          ]\n        },\n        {\n          \"name\": \"Glycine receptor-mediated inhibitory signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"GLRA1 encodes glycine receptor alpha-1 subunit, ligand-gated chloride channel involved in inhibitory neurotransmission\"\n            }\n          ],\n          \"genes\": [\n            \"GLRA1\"\n          ]\n        },\n        {\n          \"name\": \"Guanylate cyclase signaling and cGMP metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"PTGER3 (prostaglandin E receptor) and related signaling including cyclic nucleotide pathways regulate cellular responses\"\n            }\n          ],\n          \"genes\": [\n            \"GUCY2C\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"NMDA receptor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"GRIN3A participates in NMDA receptor assembly and function as ligand-gated ion channel\"\n            }\n          ],\n          \"genes\": [\n            \"GRIN3A\"\n          ]\n        },\n        {\n          \"name\": \"Inhibitory neurotransmitter receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"GLRA1 represents ligand-gated chloride channel mediating inhibitory synaptic transmission\"\n            }\n          ],\n          \"genes\": [\n            \"GLRA1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Retention of partial neuronal identity supporting stem cell-like program maintenance\",\n        \"Dysregulation of glutamate homeostasis potentially contributing to excitotoxicity and microenvironment remodeling\",\n        \"Altered serotonin signaling potentially affecting immune cell recruitment and mood-related neuropathology\",\n        \"Aberrant inhibitory signaling potentially affecting neural circuit function surrounding tumor\",\n        \"Enhanced plasticity toward neuronal phenotypes in specific tumor subpopulations\"\n      ],\n      \"evidence_summary\": \"The presence of neurotransmission-related genes in the astrocytoma candidate set reflects the neuronal developmental origin of astrocytes and the potential for tumor-initiating cells or specific tumor populations to retain or activate neuronal differentiation programs. Emerging research has established that trans-differentiation events occur in neural tumors, and that retention of neuronal identity markers correlates with specific cellular states and therapeutic responses. TPH2, while not classically considered a glioma gene, may support serotonergic signaling affecting both tumor cells and infiltrating immune populations. GRIN3A expression suggests potential dysregulation of glutamate signaling with implications for both tumor microenvironment acidification and neuroinflammation. The inclusion of GLRA1 (glycine receptor) is particularly intriguing, as it suggests potential participation in inhibitory signaling networks that might suppress immune responses or neuronal activity surrounding tumors.\",\n      \"significance_score\": 0.48,\n      \"citations\": [\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"TPH2 involved in serotonin metabolic pathway regulation in brain; mutations implicated in various neuropsychiatric conditions\"\n        },\n        {\n          \"source_id\": \"30\",\n          \"notes\": \"Neurotransmission-related genes dysregulated in reactive astrocytes following traumatic brain injury\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"TPH2\",\n        \"GRIN3A\",\n        \"GLRA1\",\n        \"GUCY2C\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SLC6A3\",\n          \"SLC6A5\",\n          \"GABA_RECEPTORS\",\n          \"SEROTONIN_RECEPTORS\",\n          \"NMDA_RECEPTOR_SUBUNITS\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"31\",\n            \"notes\": \"Neurotransmitter systems require multiple components including receptors, transporters, and synthesizing enzymes\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Solute Transport and Metabolic Exchange\",\n      \"description\": \"The candidate gene set contains extensive representation of genes encoding solute carrier proteins and specific transporters including SLC7A11, SLC10A1, SLC2A9, and SLC9C2, which mediate the movement of specific molecular substrates across cellular membranes. These transporters control intracellular concentrations of amino acids, glucose, metabolites, and ions, fundamentally determining the metabolic capacities and redox state of astrocytoma cells. The coordinated expression of multiple solute carriers suggests sophisticated modification of metabolic and ion transport profiles to support rapid proliferation, resist oxidative stress, and maintain pH homeostasis in the acidic tumor microenvironment.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Cystine/glutamate transport and ferroptosis regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"SLC7A11 (xCT) cystine transporter central to ferroptosis regulation and cancer nutrient dependency\"\n            }\n          ],\n          \"genes\": [\n            \"SLC7A11\"\n          ]\n        },\n        {\n          \"name\": \"Bile acid and organic anion transport\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"SLC10A1 (NTCP) originally identified as bile acid transporter; recent research reveals roles in pathogen defense and immune responses\"\n            }\n          ],\n          \"genes\": [\n            \"SLC10A1\"\n          ]\n        },\n        {\n          \"name\": \"Glucose and polyol transport\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"SLC2A9 (GLUT9) represents glucose transporter with broader substrate specificity including urate and polyols\"\n            }\n          ],\n          \"genes\": [\n            \"SLC2A9\"\n          ]\n        },\n        {\n          \"name\": \"Ion transport and pH homeostasis\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"SLC9C2 represents solute carrier family member involved in ion transport and cellular pH regulation\"\n            }\n          ],\n          \"genes\": [\n            \"SLC9C2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Solute carrier family transporters\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"SLC proteins represent major family of membrane transporters controlling nutrient uptake and waste export\"\n            }\n          ],\n          \"genes\": [\n            \"SLC7A11\",\n            \"SLC10A1\",\n            \"SLC2A9\",\n            \"SLC9C2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced amino acid and glucose uptake supporting biosynthetic demands of rapid proliferation\",\n        \"Maintenance of intracellular redox balance through cystine availability\",\n        \"Modified responsiveness to nutrient scarcity through transporter regulation\",\n        \"Enhanced resistance to ferroptosis through SLC7A11-dependent cystine uptake\",\n        \"Altered pH homeostasis through coordinated ion transport enabling survival in acidic tumor microenvironment\"\n      ],\n      \"evidence_summary\": \"The solute transport program represents a fundamental aspect of astrocytoma metabolic adaptation. SLC7A11 (xCT) has been exceptionally well-characterized through ferroptosis research, with clear mechanistic roles in cystine uptake and glutathione synthesis. SLC2A9 (GLUT9) represents an emerging therapeutic target in various malignancies through its roles in glucose and urate transport. The inclusion of multiple distinct solute carriers suggests that astrocytomas employ comprehensive fine-tuning of metabolic substrate selection and ion homeostasis. Recent research has established that transporter expression profiles differ substantially between tumor regions (hypoxic versus normoxic, proliferative versus quiescent), suggesting dynamic regulation of this program in response to microenvironmental changes.\",\n      \"significance_score\": 0.66,\n      \"citations\": [\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"SLC7A11 inhibition as therapeutic strategy in cancer targeting cystine dependence and ferroptosis resistance\"\n        },\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"Metabolic transporter expression patterns reflect tumor microenvironmental heterogeneity\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SLC7A11\",\n        \"SLC10A1\",\n        \"SLC2A9\",\n        \"SLC9C2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SLC1A1\",\n          \"SLC1A2\",\n          \"SLC6A6\",\n          \"SLC6A7\",\n          \"SLC43A1\",\n          \"SLC43A2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"31\",\n            \"notes\": \"Additional solute carriers control amino acid uptake, neurotransmitter transport, and metabolite exchange\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Pathway databases and published experimental evidence\",\n      \"Functional annotation of gene families\",\n      \"Co-expression patterns in glioma and related cell types\",\n      \"Protein-protein interaction networks\",\n      \"Literature mining focusing on astrocyte and glioma biology\",\n      \"Integration of single-cell transcriptomics data from brain tumors and normal astrocytes\"\n    ],\n    \"notes\": \"Analysis prioritized genes with well-established functions in documented biological pathways relevant to astrocytoma progression. Where experimental evidence was limited (e.g., many lncRNAs, meiosis-related genes, ciliary genes), programs were designated with lower significance scores reflecting the need for further investigation. Programs were designed to be mechanistically coherent, representing actual biological modules rather than loosely related gene collections. Cross-program interactions were noted but programs were kept functionally distinct to enable targeted investigation.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n---\n\n## Final Synthesis and Future Directions\n\nThe comprehensive analysis of 215 candidate genes in the context of astrocytoma has yielded identification of twelve functionally coherent gene programs spanning immune signaling, metabolic adaptation, cellular mechanics, and developmental plasticity. The significance and novelty of this analysis lie in the systematic integration of individual gene functions into coordinated programs that reflect how astrocytoma cells achieve malignant transformation and maintenance.\n\nSeveral overarching themes emerge from this analysis. First, the candidate gene set exhibits substantial convergence with genes dysregulated in reactive astrocytes following traumatic brain injury, suggesting that malignant transformation may involve selective fixation or dysregulation of normally plastic astrocytic states. Second, the prominent representation of lncRNAs suggests that post-transcriptional and non-coding RNA-mediated regulation represent prioritized regulatory layers in astrocytoma, potentially explaining observed discrepancies between genomic alterations and phenotypic outcomes.\n\nThird, the presence of genes regulating ferroptosis resistance, Hippo pathway signaling, and mechanotransduction suggests that astrocytomas exploit or dysregulate pathways originally evolved for tissue-level force balance and cell competition. The integration of these mechanistic insights with clinical observations of astrocytoma progression will enable development of rationally designed combination therapies targeting coordinated gene programs rather than individual genes.\n\nFuture investigations should prioritize functional validation of predicted gene program functions through CRISPR-mediated perturbation screens, integration with patient-derived astrocytoma models, and correlation of gene expression patterns with clinical outcomes. The systematic framework developed through this analysis provides a foundation for mechanistic understanding of astrocytoma biology and identification of rational therapeutic targets.",
    "citations": [
      "https://www.ncbi.nlm.nih.gov/gene/3824",
      "https://www.ncbi.nlm.nih.gov/gene/16643",
      "https://www.nature.com/articles/s41419-025-08155-1",
      "https://www.ncbi.nlm.nih.gov/gene/4128",
      "https://www.nature.com/articles/s41467-025-66690-z",
      "https://www.ncbi.nlm.nih.gov/gene/25937",
      "https://www.ncbi.nlm.nih.gov/gene/9173",
      "https://www.ncbi.nlm.nih.gov/gene/3554",
      "https://www.ncbi.nlm.nih.gov/gene/5733",
      "https://www.ncbi.nlm.nih.gov/gene/353376",
      "https://www.ncbi.nlm.nih.gov/gene/7098",
      "https://www.ncbi.nlm.nih.gov/gene/148022",
      "https://www.ncbi.nlm.nih.gov/gene/7057",
      "https://www.nature.com/articles/s41419-025-08204-9",
      "https://www.ncbi.nlm.nih.gov/gene/23657",
      "https://www.nature.com/articles/s41418-025-01642-0",
      "https://www.nature.com/articles/s41467-025-66985-1",
      "https://www.ncbi.nlm.nih.gov/gene/8651",
      "https://www.nature.com/articles/s41419-025-08254-z",
      "https://www.ncbi.nlm.nih.gov/gene/6777",
      "https://www.ncbi.nlm.nih.gov/gene/6678",
      "https://www.ncbi.nlm.nih.gov/gene/29126",
      "https://www.ncbi.nlm.nih.gov/gene/4015",
      "https://www.nature.com/articles/s41419-025-08289-2",
      "https://www.ncbi.nlm.nih.gov/gene/8678",
      "https://www.ncbi.nlm.nih.gov/gene/4780",
      "https://www.ncbi.nlm.nih.gov/gene/3569",
      "https://www.ncbi.nlm.nih.gov/gene/7103",
      "https://www.ncbi.nlm.nih.gov/gene/977",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://www.nature.com/articles/s41598-025-11796-z"
    ],
    "duration_seconds": 253.12346696853638
  }
}